In vivo tumor growth inhibition study

Tumor growth inhibition (TGI) studies were conducted in primary patient NSCLC tumor (LXF A677) bearing mice receiving erlotinib or gefitinib treatment. Experimental details have been previously described elsewhere [31]. In summary, the mice were randomized into 7 groups with 8 animals per group. Each group received either low, mid or high dose of erlotinib or gefitinib or vehicle only (control group). The drugs were administered orally once per day for 14 days. Tumor volume was monitored by caliper measurements over 30 days and sparse PK samples were collected. The detection limit for tumor volume was 5 mm³. The experimental study design is summarized in table S1, supplementary material. An overview of missing data due to early determination and data below limit of quantification is summarized in supplementary table S2.